Inhibrx, Inc. (NASDAQ:INBX) CEO Acquires $316,200.00 in Stock

Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe purchased 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was acquired at an average cost of $15.81 per share, for a total transaction of $316,200.00. Following the transaction, the chief executive officer now owns 165,000 shares in the company, valued at approximately $2,608,650. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mark Lappe also recently made the following trade(s):

• On Thursday, August 29th, Mark Lappe acquired 10,000 shares of Inhibrx stock. The stock was bought at an average cost of $14.03 per share, with a total value of $140,300.00.

Inhibrx Trading Up 9.5 %

NASDAQ:INBX traded up $1.39 on Tuesday, hitting $15.95. The stock had a trading volume of 290,343 shares, compared to its average volume of 183,656. Inhibrx, Inc. has a 1 year low of $10.80 and a 1 year high of $18.95. The firm’s fifty day simple moving average is $13.33 and its two-hundred day simple moving average is $25.17.

Inhibrx (NASDAQ:INBX) last announced its quarterly earnings data on Tuesday, August 13th. The company reported $125.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.60) by $129.08. The business had revenue of $0.10 million during the quarter. On average, equities analysts expect that Inhibrx, Inc. will post 87.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Inhibrx

Several institutional investors have recently bought and sold shares of INBX. AJOVista LLC bought a new stake in shares of Inhibrx in the fourth quarter valued at approximately $26,000. Charles Schwab Investment Management Inc. raised its stake in shares of Inhibrx by 8.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 229,866 shares of the company’s stock valued at $8,735,000 after purchasing an additional 17,762 shares during the period. E Fund Management Co. Ltd. purchased a new stake in Inhibrx during the 4th quarter worth about $209,000. Quadrant Capital Group LLC purchased a new position in Inhibrx during the 4th quarter valued at about $26,000. Finally, HCR Wealth Advisors bought a new stake in shares of Inhibrx during the fourth quarter valued at about $239,000. Hedge funds and other institutional investors own 82.46% of the company’s stock.

Analysts Set New Price Targets

Separately, JMP Securities started coverage on Inhibrx in a report on Tuesday, July 23rd. They set a “market perform” rating for the company.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.